"Counterfeit drug networks expose systemic gaps in India's pharmaceutical regulatory architecture." Discuss the institutional and legal framework for drug regulation in India and suggest reforms to strengthen supply-chain traceability.

A "spurious drug" under Section 17B of the Drugs and Cosmetics Act, 1940 is one that imitates or falsely represents another product [1][2]. Recent busts of inter-State rackets supplying counterfeit cancer and ICU medicines to hospitals show that India's regulatory architecture, though legally stringent, is institutionally fragmented at the point of distribution.

Institutional framework

• CDSCO, under the Directorate General of Health Services (Ministry of Health & Family Welfare), is India's National Regulatory Authority — approving new drugs, clinical trials and imports, and setting standards [1].
• State Drugs Controllers license manufacture, sale and distribution within States; manufacturing licences now require joint inspection by central and State drug inspectors [3].
• Enforcement against organised rackets rests largely with State police/SITs, with CDSCO–State risk-based inspections of high-risk units as the preventive arm — over 900 units inspected since December 2022, yielding stop-production orders and licence cancellations [4].

Legal framework and its gaps

• The Act of 1940 and Rules of 1945 govern quality, labelling and licensing; the 2008 Amendment made spurious-drug offences cognizable and non-bailable, with imprisonment up to life and heavy fines, and special courts have been designated in most States for speedy trial [3].
• Yet gaps persist: jurisdiction ends at State borders while networks operate across them; unlicensed repackaging units escape a licence-centric inspection regime; there is no end-to-end batch traceability from manufacturer to patient; and hospital procurement lured by steep discounts performs weak due diligence.

Reforms for traceability

• Accelerate and widen the Schedule H2 QR-code track-and-trace framework, already extended to vaccines, antimicrobials and anti-cancer drugs, to all formulations [5].
• Build a unified national drug authentication registry linking licences, batches and invoices, with mandatory e-verification before institutional purchase.
• Institutionalise a central coordination mechanism for inter-State investigations and strengthen drug inspector cadres.

Counterfeit drugs violate the right to health under Article 21. Marrying stringent law with digital traceability and cooperative federal enforcement can secure both patient safety and India's standing as the world's pharmacy.